EZM 2302

EZM 2302 is an inhibitor of coactivator-associated arginine methyltransferase 1 ( CARM1 ) with an IC 50 of 6 nM.In VitroEZM 2302 binds to CARM1 and is a selective inhibitor of CARM1 activity (IC 50 =6 nM) with broad selectivity against other histone methyltransferases. Treatment of MM cell lines with EZM 2302 leads to inhibition of PABP1 and SMB methylation and cell stasis with IC 50 values in the nanomolar range (9, 31 nM, respectively). EZM 2302 inhibits the in vitro proliferation of multiple hematopoietic cell lines, with day 14 IC 50 values of less than 100 nM in 9 of 15 cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoEZM 2302 is stable in human hepatocytes (CL<3 mL/min/kg), and moderately binds to human, mouse and rat plasma proteins with a mean fraction unbound of 0.66, 0.46 and 0.74, respectively. In mouse and rat, the plasma clearance (CL) is 43 and 91 mL/min/kg, respectively. EZM 2302 shows dose-dependent exposure and tumor growth inhibition (TGI) after 21 days in the RPMI-8226 xenograft model. Tumors in all EZM 2302 dose groups measured on day 21 show significant decreases in tumor growth compared to vehicle . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC50: 6 nM (CARM1)

Specifications & Purity: EZM 2302 is an inhibitor of coactivator-associated arginine methyltransferase 1 ( CARM1 ) with an IC 50 of 6 nM.In VitroEZM 2302 binds to CARM1 and is a selective inhibitor of CARM1 activity (IC 50 =6 nM) with broad selectivity against other histone methyltransferases. Treatment of MM cell lines with EZM 2302 leads to inhibition of PABP1 and SMB methylation and cell stasis with IC 50 values in the nanomolar range (9, 31 nM, respectively). EZM 2302 inhibits the in vitro proliferation of multiple hematopoietic cell lines, with day 14 IC 50 values of less than 100 nM in 9 of 15 cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoEZM 2302 is stable in human hepatocytes (CL<3 mL/min/kg), and moderately binds to human, mouse and rat plasma proteins with a mean fraction unbound of 0.66, 0.46 and 0.74, respectively. In mouse and rat, the plasma clearance (CL) is 43 and 91 mL/min/kg, respectively. EZM 2302 shows dose-dependent exposure and tumor growth inhibition (TGI) after 21 days in the RPMI-8226 xenograft model. Tumors in all EZM 2302 dose groups measured on day 21 show significant decreases in tumor growth compared to vehicle . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC50: 6 nM (CARM1)

Grade: Moligand™

Molecular Formula: C29H37ClN6O5

Molecular Weight: 585.09

PubChem CID: 90425581

Isomeric SMILES: CC1=C(N=C(N=C1N2CC3(C2)CCN(CC3)C(=O)OC)C4=C(C=CC(=C4)OC[C@@H](CNC)O)Cl)C5=C(ON=C5C)C

Storage Temperature: Store at -20°C

Shipped in: Ice chest + Ice pads

UPC:

51442720

Weight:

1.06 Ounces

HazmatClass:

Yes

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

E648190-1mg

Country of Origin:

China

CAS:

1628830-21-6

Product Size:

1mg

Harmonized Tariff Code:

2931.90.90